Safety, Tolerability, and Immunogenicity of a Cytomegalovirus DNA Vaccine
Status:
Withdrawn
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
If the participant decides to take part in the study, the participant will need to do the
following:
Visit the study clinic up to 10 times and be available for a reasonable amount of follow up
phone calls to see how the participant is doing.
The participant will receive three doses of vaccine injected into the muscle of the upper
arm. After each injection the participant will be asked to remain at the study site for at
least 30 minutes after the participant receives the study vaccine.
The results of all of the participants blood tests, just like all other laboratory test
results, will be provided to the Investigators, Sponsor, and vaccine developer. Positive HIV
and viral hepatitis test results will be reportable to local health authorities according to
local laws.
The participant will be asked to refrain from excessive physical activities and alcohol
consumption within 2 days before each clinic visit to avoid possible confusing effects on
laboratory tests.